In more detail, the uptake of H19 packaged in exosomes by lung cancer cells could result in the upregulation of H19 expression in these recipient cells and thereby cause cancer cell resistance to gefitinib, but H19 knockdown could contribute to the recovery of gefitinib sensitivity. Here, H19 is linked to lung carcinoma.